Peptide News

Trials, approvals and rules, from official sources only. Updated October 12, 2026.

Clinical trial · October 12, 2026

Orforglipron's highest dose showed greater weight loss than one oral semaglutide dose in an indirect comparison

Eli Lilly and Company announced on September 29, 2026 the results of an indirect treatment comparison in which its highest orforglipron (Foundayo) dose was associated with greater weight loss and greater A1C reduction than the comparator oral semaglutide dose at 52 weeks in adults with type 2 diabetes.

Clinical trial · October 8, 2026

Retatrutide lowers weight and A1C in Phase 3 TRIUMPH-2 trial

Pipeline tracker

Source: ClinicalTrials.gov, refreshed daily

Molecule	Company	Most advanced phase	Countries with trial sites
Retatrutide	Eli Lilly	Phase 3	38
Orforglipron	Eli Lilly	Phase 4	44
CagriSema (cagrilintide + semaglutide)	Novo Nordisk	Phase 3	44
Survodutide	Boehringer Ingelheim	Phase 3	46
MariTide (maridebart cafraglutide)	Amgen	Phase 3	36
Amycretin	Novo Nordisk	Phase 3	34

Legal status by country

What the rules say about peptides in the United States, the European Union and other countries, with official sources.

See the legal status

Get peptide news first

A weekly digest, official sources only.

Newsletter

News for information only. Not medical or legal advice. No dosing recommendations.